Galectin Therapeutics
GALT
GALT
66 hedge funds and large institutions have $12.3M invested in Galectin Therapeutics in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
less ownership
Funds ownership: →
29% less capital invested
Capital invested by funds: $17.4M → $12.3M (-$5.09M)
38% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 16
Holders
66
Holding in Top 10
–
Calls
$45K
Puts
$23K
Top Buyers
| 1 | +$308K | |
| 2 | +$184K | |
| 3 | +$119K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$79.9K |
| 5 |
Jane Street
New York
|
+$56.1K |
Top Sellers
| 1 | -$3.36M | |
| 2 | -$124K | |
| 3 | -$108K | |
| 4 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
-$19.9K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$19.3K |